JOSEPHINE KARL: Open Payments
NPI 1316051071 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,740 in 180 payments from 21 companies in 2025. Trend: 2023 $4,103 · 2024 $4,003 · 2025 $3,740
Food & beverage: $3,574Education: $165
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 25 | $530 |
| Regeneron Healthcare Solutions, Inc. | 17 | $495 |
| GENZYME CORPORATION | 15 | $487 |
| ABBVIE INC. | 29 | $451 |
| Janssen Biotech, Inc. | 12 | $289 |
| Amgen Inc. | 11 | $251 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 13 | $191 |
| Incyte Corporation | 9 | $177 |
| Novartis Pharmaceuticals Corporation | 7 | $137 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 13 | $136 |
Products named: DUPIXENT, Bimzelx, TREMFYA, Otezla, SKYRIZI, OPZELURA, Cabtreo, RINVOQ.
Industry payments across TX — which companies pay providers there.
